With FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And Reward

RBC Capital Markets has downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) as it weighs recent investor feedback, company commentary, and public statements from senior FDA officials.

The analyst reports that after extensive discussions with investors over the past several weeks, expectations for the FDA’s label decision on Elevidys have significantly increased, especially with shares now up 50% in the last six months.

“We believe many investors expect at least an expanded label to cover 6yo+ ambulatory pts, which, while still a reasonably likely scenario in our view, now seems more baked in,” RBC writes.

Also Read: Second Death – Pfizer Reports Young Boy’s Death After One Year Of …

Full story available on Benzinga.com